* Mandatory fields

^† Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation All information you provide in this site will be governed by our Privacy Policy.

Product availability may vary by country specific regulatory requirements and approvals. Contact your country representative for further details.
The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay is intended for in vitro diagnostic use.
In the United States:

• Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.
• This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
• This product has been authorized only for the detection and differentiation of nucleic acid from SARS-CoV-2, influenza A virus, influenza B virus, and/or Respiratory Syncytial Virus, not for any other viruses or pathogens; and
• The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.